TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03650205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: Ivabradine capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule.
Study: NCT03959501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: Dapagliflozin 10mg daily for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg
Description: Sitagliptin 100mg daily for 24 weeks
Study: NCT02806986

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGSC 20%
Description: Weekly administration of IGSC 20% via intravenous infusion
Study: NCT03038373

Intervention type: PROCEDURE
Intervention: Laparoscopic Sleeve Gastrectomy
Description: Laparoscopic Sleeve Gastrectomy will be conducted based on standard protocol.

Intervention type: PROCEDURE
Intervention: Laparoscopic Sleeve Gastrectomy
Description: Laparoscopic Sleeve Gastrectomy will be conducted based on standard protocol.
Study: NCT06089304

Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention (PCI) is a catheter-based technique performed under fluoroscopic guidance to treat coronary artery disease and restore blood flow to the myocardium. During PCI, coronary vessel patency is generally achieved with drug-eluting stents, which are metallic scaffolds coated with a polymer that carry and gradually release an antiproliferative drug. In the present study, all participants underwent PCI with implantation of a thin-strut, cobalt-chromium, durable-fluorinated polymer, everolimus-eluting stent (XIENCE, Abbott), and received a course of dual antiplatelet therapy (DAPT) ranging from 28 to 365 days after PCI.

Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention (PCI) is a catheter-based technique performed under fluoroscopic guidance to treat coronary artery disease and restore blood flow to the myocardium. During PCI, coronary vessel patency is generally achieved with drug-eluting stents, which are metallic scaffolds coated with a polymer that carry and gradually release an antiproliferative drug. In the present study, all participants underwent PCI with implantation of a thin-strut, cobalt-chromium, durable-fluorinated polymer, everolimus-eluting stent (XIENCE, Abbott), and received a course of dual antiplatelet therapy (DAPT) ranging from 28 to 365 days after PCI.
Study: NCT02063503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: every group receives 2 treatments every week during 9 consecutive weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: every group receives 2 treatments every week during 9 consecutive weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: every group receives 2 treatments every week during 9 consecutive weeks
Study: NCT00499187

Intervention type: PROCEDURE
Intervention: Blood Draws
Description: A single whole blood sample was collected for genomic analysis.

Intervention type: PROCEDURE
Intervention: Blood Draws
Description: A single whole blood sample was collected for genomic analysis.
Study: NCT03566719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Intervention group has been submitted to an exercise program directed to prevent and reduce fall risk
Study: NCT01278446

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extensively hydrolyzed, casein protein infant formula
Description: Commercially available hydrolyzed infant formula
Study: NCT02292407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LigaSure Precise instrument
Description: LigaSure Precise instrument is used during Axillary Lymph Node Dissection Technique: Dead space closure Technique: Omission of postoperative drain
Study: NCT02272972

Intervention type: OTHER
Intervention: Application of knowledge
Description: Educational Intervention has been performed at the treating surgeon (video and poster). The surgeons applies the achieved knowledge when performing the intraoperative fluoroscopy in patients with pertrochanteric fractures.
Study: NCT02954432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: Subjects will receive 20 minutes of either active or sham tDCS at an intensity of 2 milliamps (mA). The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.
Study: NCT02566837

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: ultrasound imaging to guide the intramuscular injections of botulinum toxin : Ultrasound is used to identify the target muscle, and for guiding the insertion of the needle in the muscle. Once the needle is positioned, the botulinum toxin is injected

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: electrical stimulation
Description: electrical stimulation (reference technique currently recommended over muscle palpation and anatomical landmarks) to guide intramuscular injections of botulinum toxin. Intramuscular injection is carried out in register with the zone where is located the theoretically target muscle. Electrical stimulation (mediated by the tip of the needle) used to verify the correct position of the needle, and reposition it if necessary. Once the needle is correctly positioned, the botulinum toxin is injected.
Study: NCT02464969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Tablet or Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Unfractionated heparin, low molecular weight heparin, and/or a vitamin K antagonist. For subjects under 2 years of age, standard of care will be limited to unfractionated heparin or low molecular weight heparin.
Study: NCT04188535

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI IMAGING
Description: Imaging with MRI will be performed as per disease site standards.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI IMAGING
Description: Imaging with MRI will be performed as per disease site standards.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI IMAGING
Description: Imaging with MRI will be performed as per disease site standards.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI IMAGING
Description: Imaging with MRI will be performed as per disease site standards.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI IMAGING
Description: Imaging with MRI will be performed as per disease site standards.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI IMAGING
Description: Imaging with MRI will be performed as per disease site standards.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI IMAGING
Description: Imaging with MRI will be performed as per disease site standards.
Study: NCT02606136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamrevlumab
Description: Pamrevlumab, 10 milligrams (mg)/milliliter (mL), single dose vials
Study: NCT05279261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The axillary approach
Description: The approach enters from the axilla through the interval between the latissimus dorsi and subscapularis to expose the anteroinferior glenoid, neck and lateral border of the scapula with entire rotator cuff sparing and fix the fracture with screws or plates.
Study: NCT00466323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Member Provider Outreach
Description: Family Member Provider Outreach is a brief recovery oriented model. THe FMPO meets with the consumer for 2-3 sessions and with the family for 2-3 sessions with the consumer's permission.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced treatment as usual (e-TAU)
Description: Enhanced treatment as usual. In this condition, the consumer is given a list of family services available including the family intervention team.
Study: NCT02954432

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation (tDCS)
Description: Subjects will receive 20 minutes of either active or sham tDCS at an intensity of 2 milliamps (mA). The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Ultrasound (TUS)
Description: Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Ultrasound (TUS)
Description: Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
Study: NCT01436097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information provision intervention
Description: Participant will have access to weekly data showing how much produce they are purchasing. No incentives will be given under this arm. They will also receiving information on weekly purchases, online resources, and weekly reminders on eating healthy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: information provision + flat incentive
Description: Participants will earn back 15% of what they spent on groceries for the week if they spend at least 15% of their total grocery budget on fresh produce in addition to receiving the same treatment as the IP arm. They will also receiving information on weekly purchases, online resources, and weekly reminders on eating healthy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information provision + tiered incentive
Description: In addition to receiving information on weekly purchases, online resources, and weekly reminders on eating healthy the participants assigned to the IP + tiered incentive group would earn back increasing percentages of their grocery spending for meeting increasing targets of produce consumption.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will have access through the Way to Health portal to web-based educational materials and recipes related to healthy eating. They will be informed they will receive up to $50 in reimbursements for completing the surveys that are part of the Way To Eat program as follows: $20 for completing the intake questionnaire and weigh-in and $30 reimbursements for completing the exit questionnaire and weigh-in.
Study: NCT03139474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropin-Releasing Hormone Analogue
Description: Triptorelin at a dose 1 mg per day from the midluteal phase of the cycle preceding the treatment cycle to day 2 of the cycle then 0.5 milligram of triptorelin will be used during the period of stimulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropin releasing hormone antagonist
Description: antagonist group :Multiple dose gonadotrophin-releasing hormone antagonist regimen will be used for ovarian stimulation 0.25 microgram per day cetrorelix will be administered from the 6th day of ovarian stimulation or from the presence of follicle 14 millimeter diameter .We will give them gonadotrophin for 5 days , Triggering by Human Chorionic Gonadotrophin will be administered for each group when size of follicle reach \> 17 millimeter .Oocytes will retrieved by transvaginal ultrasound , 34-36 hours after Human Chorionic Gonadotrophin administration .
Study: NCT00723502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin + Amoxicillin
Description: Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Amoxicillin, tablet 1000 mg b.i.d. (1 X 1000 mg tablet), oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin + Esomeprazole
Description: Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Esomeprazole, tablet, 40 mg b.i.d. (1 X 40 mg tablet), oral administration
Study: NCT04535934

Intervention type: OTHER
Intervention: Adenine 5+ (five stable-labeled nitrogens)
Description: taggant coencapsulated with an excipient

Intervention type: OTHER
Intervention: Adenine 5+ (five stable-labeled nitrogens)
Description: taggant coencapsulated with an excipient
Study: NCT01603550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Description: Sleep Deprivation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Restriction
Description: Energy Restriction
Study: NCT03843034

Intervention type: GENETIC
Intervention: Measure endometrial markers
Description: Endometrial biopsies will be taken from participants in both groups

Intervention type: GENETIC
Intervention: Measure endometrial markers
Description: Endometrial biopsies will be taken from participants in both groups
Study: NCT05915065

Intervention type: DEVICE
Group type: OTHER
Intervention: Coapt Phantom Limb Pain Management System
Description: The PLP-MS consists of (1) an expandable arm/leg cuff with electrode sensors to collect EMG signals from residual limb muscles, (2) an integrated hardware module (the Coapt Complete Control Gen2.5 system) that translates users' EMG signals into game commands, (3) game software for mobile applications, and (4) a secure, HIPAA-compliant cloud-based data storage system for storing and retrieving user data remotely.
Study: NCT02188823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Study: NCT01775137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBM100
Description: Tobramycin inhalation powder (TIP) 112mg/b.i.d
Study: NCT04331080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granexin® gel 100 μM
Description: Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Granexin® gel 100 μM
Description: Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granexin® gel 200 μM
Description: Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Granexin® gel 200 μM
Description: Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle gel
Description: Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle gel
Description: Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: Administered during the surgery, 24 hours post-surgery, and 48 hours post-surgery.
Study: NCT00777517

Intervention type: DRUG
Group type: OTHER
Intervention: Lipitor
Description: A single dose of 10 mg Lipitor tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin pediatric formulation
Description: A single dose of 10 mg atorvastatin pediatric formulation
Study: NCT02201602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glibenclamide
Study: NCT01384539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Study: NCT02192268

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEP

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HFOO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assisted Coughing
Study: NCT04574895

Intervention type: OTHER
Group type: OTHER
Intervention: Hematology Review
Description: VTE study team will review VTE risk percentages provided via automated report daily on weekdays and approach the primary team directly if the patient is appropriate for clinical antithrombotic interventions.
Study: NCT01446848

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iron supplement
Description: 325 mg tablets by mouth once a day for 1 week, then twice a day for 1 week, then three times daily for the remainder of the 3-month study period.
Study: NCT04111341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM (Gan-Lu-Yin)GLY
Description: TCM Gan-Lu-Yin 6g in the morning TCM Jia-Wei-Xiao-Yao-San, Ye-Jiao-Teng, Suan-Zao-Ren 8g in the evening for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: TCM Placebo 6g in the morning TCM Placebo 8g in the evening for 12 weeks
Study: NCT03701659

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery combinate with Endocrine therapy
Description: TUPKRP is abbreviation of transurethral plasma kinetic resection of prostate, which is an effective treatment of bladder outlet obstruction for benign prostate hyperplasia. MAB is abbreviation of Maximal androgen blockade, which is a kind of endocrinotherapy for advanced prostate cancer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine therapy
Description: MAB is abbreviation of Maximal androgen blockade, which is a kind of endocrine therapy for advanced prostate cancer.
Study: NCT01180075

Intervention type: DRUG
Intervention: tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV)
Description: Patients receiving this drug for clinical care at standard dosages will be enrolled.

Intervention type: DRUG
Intervention: tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV)
Description: Patients receiving this drug for clinical care at standard dosages will be enrolled.

Intervention type: DRUG
Intervention: tenofovir/emtricitabine (TDF/FTC)
Description: Patients receiving this drug for clinical care at standard dosages will be enrolled.

Intervention type: DRUG
Intervention: tenofovir/emtricitabine (TDF/FTC)
Description: Patients receiving this drug for clinical care at standard dosages will be enrolled.

Intervention type: DRUG
Intervention: Atazanavir (ATV)
Description: Patients receiving this drug for clinical care at 300mg with 100mg ritonavir daily will be enrolled.

Intervention type: DRUG
Intervention: Atazanavir (ATV)
Description: Patients receiving this drug for clinical care at 300mg with 100mg ritonavir daily will be enrolled.

Intervention type: DRUG
Intervention: Ritonavir
Description: Patients receiving this drug for clinical care at 100mg daily with 300mg atazanavir will be enrolled.

Intervention type: DRUG
Intervention: Ritonavir
Description: Patients receiving this drug for clinical care at 100mg daily with 300mg atazanavir will be enrolled.

Intervention type: PROCEDURE
Intervention: Phlebotomy
Description: Multiple blood draws will be performed in the study, and vary depending on the group.

Intervention type: PROCEDURE
Intervention: Phlebotomy
Description: Multiple blood draws will be performed in the study, and vary depending on the group.

Intervention type: PROCEDURE
Intervention: Phlebotomy
Description: Multiple blood draws will be performed in the study, and vary depending on the group.

Intervention type: PROCEDURE
Intervention: Phlebotomy
Description: Multiple blood draws will be performed in the study, and vary depending on the group.
Study: NCT03717532

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be receiving blood flow restriction therapy with a pressure cuff set to a placebo pressure setting.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized Tourniquet System for Blood Flow Restriction
Description: Patients will be receiving blood flow restriction therapy with a pressure cuff
Study: NCT00403546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone 80-160 mg/d
Description: Participants will be instructed to take one study capsule of ziprasidone orally twice daily (80 mg/d). After the first week, the study drug will be increased to two capsules twice daily (160 mg/d).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be instructed to take one study capsule of matching placebo orally twice daily. After the first week, the matching placebo will be increased to two capsules twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone 160 mg/d
Description: Participants will be taking open-label ziprasidone 80 mg orally twice daily for a total dose of 160 mg/d from at least 3 weeks before randomization to end of study 8 weeks after randomization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ziprasidone 160 mg/d
Description: Participants will be taking open-label ziprasidone 80 mg orally twice daily for a total dose of 160 mg/d from at least 3 weeks before randomization to end of study 8 weeks after randomization.
Study: NCT02243787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COVA322

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03632161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: isobaric bupivacaine 0.5% (0.3ml/kg) and dexmedetomidine (1 mcg/kg)

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: isobaric bupivacaine 0.5% (0.3ml/kg)
Study: NCT01592630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Description: On-Q pumps containing 0.2% ropivacaine to be attached to TAP catheters

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: On-Q pumps containing saline to be attached to TAP catheters
Study: NCT00354926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AME-133v (LY2469298)
Description: IV 4X weekly X 4